MIRA Pharmaceuticals Shares Are Trading Higher After the Company Announced a Recent Pre-clinical Study in Rats Demonstrated That Ketamir-2 Produced a Significant Reversal of Neuropathic Pain, Induced by Nerve Ligation, Culminating in a 100%...

MIRA製藥股份在公司宣佈最近的一項大鼠前臨床研究顯示，Ketamir-2顯著逆轉了由神經結紮引起的神經病性疼痛，最終導致100%的...

Benzinga · 08/26 20:43

MIRA Pharmaceuticals Shares Are Trading Higher After the Company Announced a Recent Pre-clinical Study in Rats Demonstrated That Ketamir-2 Produced a Significant Reversal of Neuropathic Pain, Induced by Nerve Ligation, Culminating in a 100% Normalization of Pain Thresholds at the Highest Dose.

MIRA製藥股價上漲，因該公司宣佈最近的一項臨床前研究在大鼠中表明Ketamir-2能夠顯著逆轉神經病理性疼痛，通過神經結紮誘導的疼痛，在最高劑量下疼痛閾值完全恢復正常。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。